Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.63% is in line with its 5-year average of 74.72%, near the high end of its 5-year range (68.83%–82.83%).
0.42% above its 12-month average of 79.30%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 82.83%.
GROSS MARGIN
79.63%
GROSS MARGIN AVG TTM
79.30%
GROSS MARGIN AVG 3Y
76.25%
GROSS MARGIN AVG 5Y
74.72%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.42%
CURRENT VS 3Y AVG
+4.43%
CURRENT VS 5Y AVG
+6.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+92.44%
vs the sector median at left
Market Cap
$435.61M
Gross Margin
-7.06%
TTM Avg
11.69%
3Y Avg
16.80%
5Y Avg
11.20%
Market Cap
$426.51M
Gross Margin
73.89%
TTM Avg
76.35%
3Y Avg
-237.05%
5Y Avg
-138.49%
Market Cap
$438.07M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$439.55M
Gross Margin
99.82%
TTM Avg
1.85%
3Y Avg
-144.74%
5Y Avg
-84.51%
Market Cap
$424.10M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
Market Cap
$422.86M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$422.72M
Gross Margin
27.57%
TTM Avg
28.87%
3Y Avg
27.37%
5Y Avg
25.35%
Market Cap
$442.34M
Gross Margin
100.00%
TTM Avg
97.93%
3Y Avg
98.97%
5Y Avg
99.31%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $431.97M | 79.63% | 79.30% | 76.25% | 74.72% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | -7.06% | 11.69% | 16.80% | 11.20% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | 73.89% | 76.35% | -237.05% | -138.49% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | 99.82% | 1.85% | -144.74% | -84.51% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 42.92% | 41.39% | 40.24% | 40.24% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 27.57% | 28.87% | 27.37% | 25.35% |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | 100.00% | 97.93% | 98.97% | 99.31% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 61.77% | 80.89% | 90.44% | -1369.52% |
Gross Margin
79.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 82.83% |
| 2026-03-31 | 81.78% |
| 2025-12-31 | 77.40% |
| 2025-09-30 | 77.39% |
| 2025-06-30 | 77.09% |
| 2025-03-31 | 76.99% |
| 2024-12-31 | 75.41% |
| 2024-09-30 | 73.22% |
| 2024-06-30 | 73.40% |
| 2024-03-31 | 73.62% |
| 2023-12-31 | 75.20% |
| 2023-09-30 | 74.47% |
| 2023-06-30 | 72.51% |
| 2023-03-31 | 71.67% |
| 2022-12-31 | 68.83% |
| 2022-09-30 | 71.39% |
| 2022-06-30 | 73.20% |
| 2022-03-31 | 72.61% |
| 2021-12-31 | 73.44% |
| 2021-09-30 | 72.61% |
| 2021-06-30 | 74.10% |
| 2021-03-31 | 75.72% |
| 2020-12-31 | 76.44% |
| 2020-09-30 | 74.97% |
| 2020-06-30 | 70.96% |
| 2020-03-31 | 70.75% |
